Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Cash & Equivalents (2022 - 2025)

CervoMed's Cash & Equivalents history spans 9 years, with the latest figure at $9.4 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents changed N/A year-over-year to $9.4 million; the TTM value through Sep 2025 reached $9.4 million, changed N/A, while the annual FY2024 figure was $9.0 million, 15.48% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $9.4 million at CervoMed, up from $8.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $15.0 million in Q2 2023 and bottomed at $4.1 million in Q4 2022.
  • The 4-year median for Cash & Equivalents is $9.2 million (2024), against an average of $9.1 million.
  • The largest annual shift saw Cash & Equivalents soared 151.43% in 2023 before it tumbled 56.51% in 2024.
  • A 4-year view of Cash & Equivalents shows it stood at $4.1 million in 2022, then skyrocketed by 90.37% to $7.8 million in 2023, then grew by 15.48% to $9.0 million in 2024, then grew by 4.87% to $9.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Cash & Equivalents are $9.4 million (Q3 2025), $8.3 million (Q2 2025), and $10.5 million (Q1 2025).